Cargando…

Pharmacokinetics and dose adjustment of etoposide administered in a medium-dose etoposide, cyclophosphamide and total body irradiation regimen before allogeneic hematopoietic stem cell transplantation

BACKGROUND: We investigated the pharmacokinetics of etoposide (ETP) to reduce the inter-individual variations of ETP concentrations in patients with acute leukemia who underwent allogeneic hematopoietic stem cell transplantation. We also carried out an in vivo study using rats to verify the dose adj...

Descripción completa

Detalles Bibliográficos
Autores principales: Tazawa, Yuki, Shigematsu, Akio, Kasashi, Kumiko, Sugita, Junichi, Endo, Tomoyuki, Kondo, Takeshi, Teshima, Takanori, Iseki, Ken, Sugawara, Mitsuru, Takekuma, Yoh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4976473/
https://www.ncbi.nlm.nih.gov/pubmed/27504190
http://dx.doi.org/10.1186/s40780-016-0052-9
_version_ 1782446879309561856
author Tazawa, Yuki
Shigematsu, Akio
Kasashi, Kumiko
Sugita, Junichi
Endo, Tomoyuki
Kondo, Takeshi
Teshima, Takanori
Iseki, Ken
Sugawara, Mitsuru
Takekuma, Yoh
author_facet Tazawa, Yuki
Shigematsu, Akio
Kasashi, Kumiko
Sugita, Junichi
Endo, Tomoyuki
Kondo, Takeshi
Teshima, Takanori
Iseki, Ken
Sugawara, Mitsuru
Takekuma, Yoh
author_sort Tazawa, Yuki
collection PubMed
description BACKGROUND: We investigated the pharmacokinetics of etoposide (ETP) to reduce the inter-individual variations of ETP concentrations in patients with acute leukemia who underwent allogeneic hematopoietic stem cell transplantation. We also carried out an in vivo study using rats to verify the dose adjustment. METHODS: This study included 20 adult patients. ETP was administered intravenously at a dose of 15 mg/kg once daily for 2 days (total dose: 30 mg/kg) combined with standard conditioning of cyclophosphamide and total body irradiation. In an in vivo study using rats, ETP was administered intravenously at a dose of 15 mg/kg or an adjusted dose. The ETP plasma concentration was determined by using HPLC. The pharmacokinetic parameters were estimated by using a 1-compartment model. RESULTS: The peak concentration (C(max)) of ETP and the area under the plasma concentration-time curve (AUC) of ETP differed greatly among patients (range of C(max), 51.8 - 116.5 μg/mL; range of AUC, 870 - 2015 μg · h/mL). A significant relationship was found between C(max) and AUC (R = 0.85, P < 0.05). Distribution volume (Vd) was suggested to be one of the factors of inter-individual variation in plasma concentration of ETP in patients (range of Vd, 0.13 - 0.27 L/kg), and correlated with Alb and body weight (R = 0.56, P < 0.05; R = 0.40, P < 0.05 respectively). We predicted Vd of rats by body weight of rats (with normal albumin levels and renal function), and the dose of ETP was adjusted using predicted Vd. In the dose adjustment group, the target plasma ETP concentration was achieved and the variation of plasma ETP concentration was decreased. CONCLUSION: The results suggested that inter-individual variation of plasma concentration of ETP could be reduced by predicting Vd. Prediction of Vd is effective for reducing individual variation of ETP concentration and might enable a good therapeutic effect to be achieved.
format Online
Article
Text
id pubmed-4976473
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-49764732016-08-09 Pharmacokinetics and dose adjustment of etoposide administered in a medium-dose etoposide, cyclophosphamide and total body irradiation regimen before allogeneic hematopoietic stem cell transplantation Tazawa, Yuki Shigematsu, Akio Kasashi, Kumiko Sugita, Junichi Endo, Tomoyuki Kondo, Takeshi Teshima, Takanori Iseki, Ken Sugawara, Mitsuru Takekuma, Yoh J Pharm Health Care Sci Research Article BACKGROUND: We investigated the pharmacokinetics of etoposide (ETP) to reduce the inter-individual variations of ETP concentrations in patients with acute leukemia who underwent allogeneic hematopoietic stem cell transplantation. We also carried out an in vivo study using rats to verify the dose adjustment. METHODS: This study included 20 adult patients. ETP was administered intravenously at a dose of 15 mg/kg once daily for 2 days (total dose: 30 mg/kg) combined with standard conditioning of cyclophosphamide and total body irradiation. In an in vivo study using rats, ETP was administered intravenously at a dose of 15 mg/kg or an adjusted dose. The ETP plasma concentration was determined by using HPLC. The pharmacokinetic parameters were estimated by using a 1-compartment model. RESULTS: The peak concentration (C(max)) of ETP and the area under the plasma concentration-time curve (AUC) of ETP differed greatly among patients (range of C(max), 51.8 - 116.5 μg/mL; range of AUC, 870 - 2015 μg · h/mL). A significant relationship was found between C(max) and AUC (R = 0.85, P < 0.05). Distribution volume (Vd) was suggested to be one of the factors of inter-individual variation in plasma concentration of ETP in patients (range of Vd, 0.13 - 0.27 L/kg), and correlated with Alb and body weight (R = 0.56, P < 0.05; R = 0.40, P < 0.05 respectively). We predicted Vd of rats by body weight of rats (with normal albumin levels and renal function), and the dose of ETP was adjusted using predicted Vd. In the dose adjustment group, the target plasma ETP concentration was achieved and the variation of plasma ETP concentration was decreased. CONCLUSION: The results suggested that inter-individual variation of plasma concentration of ETP could be reduced by predicting Vd. Prediction of Vd is effective for reducing individual variation of ETP concentration and might enable a good therapeutic effect to be achieved. BioMed Central 2016-08-08 /pmc/articles/PMC4976473/ /pubmed/27504190 http://dx.doi.org/10.1186/s40780-016-0052-9 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Tazawa, Yuki
Shigematsu, Akio
Kasashi, Kumiko
Sugita, Junichi
Endo, Tomoyuki
Kondo, Takeshi
Teshima, Takanori
Iseki, Ken
Sugawara, Mitsuru
Takekuma, Yoh
Pharmacokinetics and dose adjustment of etoposide administered in a medium-dose etoposide, cyclophosphamide and total body irradiation regimen before allogeneic hematopoietic stem cell transplantation
title Pharmacokinetics and dose adjustment of etoposide administered in a medium-dose etoposide, cyclophosphamide and total body irradiation regimen before allogeneic hematopoietic stem cell transplantation
title_full Pharmacokinetics and dose adjustment of etoposide administered in a medium-dose etoposide, cyclophosphamide and total body irradiation regimen before allogeneic hematopoietic stem cell transplantation
title_fullStr Pharmacokinetics and dose adjustment of etoposide administered in a medium-dose etoposide, cyclophosphamide and total body irradiation regimen before allogeneic hematopoietic stem cell transplantation
title_full_unstemmed Pharmacokinetics and dose adjustment of etoposide administered in a medium-dose etoposide, cyclophosphamide and total body irradiation regimen before allogeneic hematopoietic stem cell transplantation
title_short Pharmacokinetics and dose adjustment of etoposide administered in a medium-dose etoposide, cyclophosphamide and total body irradiation regimen before allogeneic hematopoietic stem cell transplantation
title_sort pharmacokinetics and dose adjustment of etoposide administered in a medium-dose etoposide, cyclophosphamide and total body irradiation regimen before allogeneic hematopoietic stem cell transplantation
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4976473/
https://www.ncbi.nlm.nih.gov/pubmed/27504190
http://dx.doi.org/10.1186/s40780-016-0052-9
work_keys_str_mv AT tazawayuki pharmacokineticsanddoseadjustmentofetoposideadministeredinamediumdoseetoposidecyclophosphamideandtotalbodyirradiationregimenbeforeallogeneichematopoieticstemcelltransplantation
AT shigematsuakio pharmacokineticsanddoseadjustmentofetoposideadministeredinamediumdoseetoposidecyclophosphamideandtotalbodyirradiationregimenbeforeallogeneichematopoieticstemcelltransplantation
AT kasashikumiko pharmacokineticsanddoseadjustmentofetoposideadministeredinamediumdoseetoposidecyclophosphamideandtotalbodyirradiationregimenbeforeallogeneichematopoieticstemcelltransplantation
AT sugitajunichi pharmacokineticsanddoseadjustmentofetoposideadministeredinamediumdoseetoposidecyclophosphamideandtotalbodyirradiationregimenbeforeallogeneichematopoieticstemcelltransplantation
AT endotomoyuki pharmacokineticsanddoseadjustmentofetoposideadministeredinamediumdoseetoposidecyclophosphamideandtotalbodyirradiationregimenbeforeallogeneichematopoieticstemcelltransplantation
AT kondotakeshi pharmacokineticsanddoseadjustmentofetoposideadministeredinamediumdoseetoposidecyclophosphamideandtotalbodyirradiationregimenbeforeallogeneichematopoieticstemcelltransplantation
AT teshimatakanori pharmacokineticsanddoseadjustmentofetoposideadministeredinamediumdoseetoposidecyclophosphamideandtotalbodyirradiationregimenbeforeallogeneichematopoieticstemcelltransplantation
AT isekiken pharmacokineticsanddoseadjustmentofetoposideadministeredinamediumdoseetoposidecyclophosphamideandtotalbodyirradiationregimenbeforeallogeneichematopoieticstemcelltransplantation
AT sugawaramitsuru pharmacokineticsanddoseadjustmentofetoposideadministeredinamediumdoseetoposidecyclophosphamideandtotalbodyirradiationregimenbeforeallogeneichematopoieticstemcelltransplantation
AT takekumayoh pharmacokineticsanddoseadjustmentofetoposideadministeredinamediumdoseetoposidecyclophosphamideandtotalbodyirradiationregimenbeforeallogeneichematopoieticstemcelltransplantation